Clinical trial
Antibody Production in Immune Disorders
NCT00023504 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Terminated
Key facts
| NCT number | NCT00023504 |
|---|---|
| Title | Antibody Production in Immune Disorders |
| Official title | Evaluation of Immune Response to Vaccines in Primary Immune Disorders |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Primary Immune Deficiency |
| Intervention type | Biological |
| Interventions | Pneumovax, Rabavert, Prevnar, Tetanus diphtheria toxoid |
| Enrollment | 21 |
| Start date | Jun 13, 2002 |
| Primary completion | May 22, 2017 |
| Completion | Oct 14, 2021 |
| First posted | Sep 10, 2001 |
| Last update posted | Oct 15, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: